U.S. Markets closed

BioLine Rx Ltd (BLRX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9600-0.0200 (-2.0408%)
At close: 3:58PM EDT
People also watch
CANFCPRXPLXANTHAPRI
Full screen
Previous Close0.9800
Open0.9800
Bid0.8800 x 500
Ask1.0800 x 3000
Day's Range0.9600 - 0.9900
52 Week Range0.8000 - 1.4200
Volume412,534
Avg. Volume366,006
Market Cap88.36M
Beta-0.05
PE Ratio (TTM)-3.19
EPS (TTM)-0.3
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.33
Trade prices are not sourced from all markets
  • BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session
    Zacks2 days ago

    BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session

    BioLine Rx Ltd (BLRX) shares rise over 5% in the last trading session.

  • BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer
    Zacks12 days ago

    BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer

    BioLineRx Ltd. (BLRX) announced that its partner Genentech, has initiated a phase Ib/II study, evaluating BL-8040 in combination Tecentriq (atezolizumab) for treatment of patients with metastatic pancreatic ductal adenocarcinoma.

  • PR Newswire13 days ago

    BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration

    BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that Genentech, a member of the Roche Group, has commenced a Phase 1b/2 study for BL-8040 in combination with atezolizumab (TECENTRIQ®), Genentech's anti-PDL1 cancer immunotherapy agent, evaluating the combination in metastatic pancreatic ductal adenocarcinoma. Up to 40 patients are planned to be enrolled in this Phase 1b/2, multicenter, randomized, controlled, open-label study to evaluate the clinical response, safety and tolerability, as well as multiple pharmacodynamic parameters, of BL-8040 in combination with atezolizumab. Initially, patients will receive BL-8040 injections as priming monotherapy for five consecutive days, after which, from day 8, they will receive both BL-8040 and atezolizumab, and continue with multiple treatment cycles for up to two years or until disease progression, clinical deterioration or unacceptable toxicity.